Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uy, G.
Right arrow Articles by Vij, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uy, G.
Right arrow Articles by Vij, R
Haematologica, Vol 91, Issue 11, 1581-1582
Copyright © 2006 by Ferrata Storti Foundation

Letter

The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma

GL Uy, MH Tomasson, A Ruddell, JF DiPersio, and R Vij

Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.